Skip to Content

Generic ProAir HFA Availability

See also: Generic ProAir RespiClick, Generic ProAir Digihaler

ProAir HFA is a brand name of albuterol, approved by the FDA in the following formulation(s):

PROAIR HFA (albuterol sulfate - aerosol, metered;inhalation)

  • Manufacturer: TEVA BRANDED PHARM
    Approval date: October 29, 2004
    Strength(s): EQ 0.09MG BASE/INH [RLD] [AB2]

Has a generic version of ProAir HFA been approved?

A generic version of ProAir HFA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to ProAir HFA and have been approved by the FDA:

albuterol sulfate aerosol, metered;inhalation

  • Manufacturer: PERRIGO PHARMS CO
    Approval date: February 24, 2020
    Strength(s): EQ 0.09MG BASE/INH [AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ProAir HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dose counter for inhaler having a bore and shaft arrangement
    Patent 10,022,509
    Issued: July 17, 2018
    Assignee(s): Ivax Pharmaceuticals Ireland Norton (Waterford) Limited Teva Pharmaceuticals Ireland

    A dose counter for an inhaler, the dose counter having a display tape arranged to be incrementally driven from a tape stock bobbin onto an incremental tape take-up drive shaft, the bobbin having an internal bore supported by and for rotation about a support shaft, at least one of the bore and support shaft having a protrusion which is resiliently biased into frictional engagement with the other of the bore and support shaft with longitudinally extending mutual frictional interaction.

    Patent expiration dates:

    • May 18, 2031
      ✓ 
      Drug product
  • Dose counters for inhalers, inhalers and methods of assembly thereof
    Patent 10,022,510
    Issued: July 17, 2018
    Assignee(s): Ivax Pharmaeuticals Ireland Norton (Waterford) Limited Teva Pharmaceuticals Ireland

    A tape system for a dose counter for an inhaler, the tape system having a main elongate tape structure, dosing indicia located on the main elongate tape structure, tape positioning indicia located on the main elongate tape structure, a tape size marker located on the main elongate tape structure indicating a number of dosing indicia on the tape, and priming indicia located on the main elongate tape structure, the priming indicia being located between the dosing indicia and one end of the tape.

    Patent expiration dates:

    • May 18, 2031
      ✓ 
      Drug product
  • Dose counter for inhaler and method for counting doses
    Patent 10,086,156
    Issued: October 2, 2018
    Assignee(s): Ivax Pharmaceuticals Ireland Norton (Waterford) Limited Teva Pharmaceuticals Ireland

    A dose counter for a metered dose inhaler includes an incremental counting system for counting doses. The incremental counting system has a main body, an actuator arranged to be driven in response to canister motion and to drive an incremental output member in response to canister motion. The actuator and incremental output member are configured to have predetermined canister fire and count configurations in a canister fire sequence. The canister fire configuration is determined by a position of the actuator relative to a datum at which the canister fires medicament and the count configuration is determined by a position of the actuator relative to the datum at which the incremental count system makes an incremental count. The actuator is arranged to reach a position in the count configuration at or after a position in the canister fire configuration.

    Patent expiration dates:

    • May 18, 2031
      ✓ 
      Drug product
  • Patent 10,561,808

    Patent expiration dates:

    • January 1, 2032
      ✓ 
      Drug product
  • Suspension aerosol formulations
    Patent 7,105,152
    Issued: September 12, 2006
    Inventor(s): Schultz; Robert K. & Schultz; David W. & Moris; Robert A.
    Assignee(s): 3M Innovative Properties Company

    Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

    Patent expiration dates:

    • September 12, 2023
      ✓ 
      Drug product
  • Metered-dose inhaler
    Patent 8,132,712
    Issued: March 13, 2012
    Inventor(s): Fenlon; Derek
    Assignee(s): Ivax Pharmaceuticals Ireland

    A metered dose inhaler dose counter, the counter includes: an actuator; a rotary gear wheel having a plurality of ratchet teeth; a driver for driving the rotary gear in a step-wise fashion in response to displacement of the actuator; a pawl that prevents reverse rotation of the rotary gear; and a display coupled to the rotary gear.

    Patent expiration dates:

    • September 7, 2028
      ✓ 
      Drug product
  • Dose counters for inhalers, inhalers and methods of assembly thereof
    Patent 9,463,289
    Issued: October 11, 2016
    Assignee(s): IVAX Pharmaceuticals Ireland Norton (Waterford) Limited Teva Pharmaceuticals Ireland

    A manually operated metered dose inhaler includes a dose counter chamber including a dose display tape driven by a ratchet wheel which is driven in turn by an actuator pawl actuated by movement of a canister, the tape unwinding from a stock bobbin during use of the inhaler, a rotation regulator being provided for the stock bobbin and including a wavelike engagement surface with concavities which engage against control elements in the form of protrusions on resilient forks of a split pin thereby permitting incremental unwinding of the stock bobbin yet resisting excessive rotation if the inhaler is dropped onto a hard surface.

    Patent expiration dates:

    • May 18, 2031
      ✓ 
      Drug product
  • Patent 9,808,587

    Patent expiration dates:

    • May 18, 2031
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.